and good Thank you, afternoon, operator, everyone.
successful foundation have a and key of several establishing how company. to the we our quarter call substantial today's solid want aspects majority I are made of significant upon transformation. reviewing We build this spend and and which progress to strategic those a advances
that to to head getting want Before though, financial address on I and results position. our commercial
I recognized the quarterly numbers were disappointing.
the of reduced reality. not Our first results impacted results a significantly reflect year by for revenue. do These half this state were steady capital
and significantly second year in of confident a are We stronger flow cash perspective. a half revenue this from both
half in the weak briefly of source me optimism half. the address an Let second and share improved first our
Genesis and normalized of associated minimal timing backlog was first the system significant a Capital the far lumpy first below became half and multiple and capital elongated, shipments our orders, leading to sales are second hospital in projects inherently level. the Despite quarters. revenue of
significantly visibility revenue flow. shipments during this in of this and third recognition Our year gives into high confidence and the cash us quarter system remainder higher
to to purchase transit have additional X be shipped There upon we revenue ready down as recognition X within planned currently delivery There's and to taking the with year-end. days, signed of Genesis are be shipped systems we payments X system systems in additional place customers coming European speak, with orders those before for systems.
for systems add would ready which these being X, will hospitals and ordered The longer upon the but still beyond system revenue in an There Genesis will tender noted a accelerate. generate to of One could X $X.X to by delivery. take I waiting additional be the on delivery shipped likely dictated million currently The quarter. has a additional of those a are systems fourth X in contractual million. backlog remains requirement recognition $X deliver systems
all have X orders also We coming in and geographies, key for pipeline expect months. purchase in our we of systems the Genesis sales an active late-stage additional
Our sales. assessment had model of cash delivery this year can by is this the end first capital on receipts we I best in approximately million $XX the cash based impacted of debt. in utilization to weakness We due just cash substantial and was systems the those, the referenced. no And year with half our of with significantly
nice a our deliver. sheet, substantial revenue be would confident and incremental it have in profit the upcoming milestones more they and to balance While we will feel
Our existing mentioned balance the sheet allows key efforts. our us our Shifting to business. strategic I innovation milestones, commercialize profitably grow new on innovation now to reach our and progress
the advancing those parallel successful company. several establishing upon solid past how the to foundation which calls, full a we're and efforts On in strategic spectrum I a of reviewed build are substantial and
I'll in quarter: more the X today's significant the made success going for commercial we most in GenesisX; progress have call impactful of acquisition. APT areas focus future the last and for MAGiC; which depth on
share release FDA. and Europe in the of press excited submitting we a this publicly Let to XXX(k) and In me start afternoon, application a introduce for system the milestones, with regulatory GenesisX to mark CE GenesisX. with were obtaining key accomplishment
are proprietary upon It GenesisX the a more before, particularly magnets system. well-established GenesisX is XXXX in an the Genesis magnetic innovative robotic technology throughout and shielding pioneered and that base distributed with was entirely Niobe, and and designed mastered, builds magnetic has Stereotaxis electronics sophisticated new robotic significantly built-in navigation. the released streamlined, incorporates Stereotaxis which than newly robotic smaller third XXXX. for platform, after in
received a of performance, magnetic available have factor uncompromising ease the of by been scalability. in and intuitive use. users. It immediate our robotic same the designed responsiveness well physician It's is we towards navigation speed that commercial special real-world about is form retains GenesisX which and and supports with robust made accessibility that clinical eye reliability What has Genesis, broad
challenges adoption in translating a of and unique we physician despite in past, As We mentioned benefits in highly clinical operate into hold than growth. robotics X% interest commercial in huge market established attractive less our differentiation. market the share the which and and
technology reliance construction the line genuine at that We the interest of have creates robot. long and up impediment never extended complexity getting the hospital. full with The translating interest into hundreds launching the physician Genesis. clinical had single movement physicians organizational since of end on expressed hospital in XX% Over largest time along the our is
room entails planning and and installation construction the Niobe shielding room. of the installation. room room, accommodate and accommodate their an and the Our significant Genesis control operating of system to structural work extensive walls, a pounds including of magnetic cabin of systems to electrical thousands the floor, architectural modification, between through in Preparing reinforcement conduits high-power operating require cabling
potential more the before stall actual terms importantly, to a fruition, to we a comes the long translating coordinating interested purchase sale complexity where process. In and but robotic architects cost leads work cases adds hospital, sales interest through in or contractors This for many deals use. planners, complex into multiyear of and of The cycle into customers the site fortunate
of or standard through operating using the the used no your and the need power to requires to stored a The magnetic system's floor smaller GenesisX magnets walls placement from in otherwise outlets. itself, a the structural operates base are rooms. for was or us anchoring XXX-volt into same XXX built fielding model negating shielding laptop GenesisX in iPhone. model. installed for robotic allows transition construction The the
smaller in than fit cabinet can control table operating dedicated cabinet the a robot Niobe. than separate cabinet of room. GenesisX from bundles and XX% cable in XX% each with or Genesis of room of volume A to is itself under compared its fiber Genesis the the routed and the XX% reduced is to cabinet to The system single rather the thin routed cabinet or a
a able viable GenesisX We a and for labs. expect to the weekend be to for over install system solution of majority the be to
to support and We operations. designed scalability for Also two of number identical and GenesisX important. chain, Accessibility reduces other is manufacturing a and customers Niobe. rather This unique to robot improved substantially assembly is and manufacturing components each The important in simplifying primary of management the like operations. or mirrors each improving Genesis GenesisX installation the sides chain supply of of ensuring other than in are GenesisX, testing. supply
magnets grades site. allows site grades Simplifying capabilities. We're and our ] to rapid The XX be and spent the system Genesis shipping to nearly installation the X with us big installed organizational aligned shipping requirements on strength shipped with reducing installation [ for of scaling the those planning, with without time per fully already less assembled scale GenesisX. will from investment business
model a for confidently rapid or to complex clinical minor, into offer more may construction a and construction a sound from interest it a model use. alternative streamlined is planning but world enables adoption. us of placement translation Transitioning freed financial from Being models clinical difference. of to allows It
GenesisX premium operating lease over it will available will disposable demand placement While Genesis, or with be a for commitment. for purchase,
are comes there's realistically of then field robotic at of magnetic systems. in that our FDA reasonable As and business to envision GenesisX We review clearance the supporting an transform Obtaining surgery, positively scaling major year-end. is look milestones. markets. to endovascular EP universe to the it us the and XXX(k) regulatory room thousands CE can architecture that allows easily GenesisX, a broader of submission large forward and for our by mark we navigation expect look filing
done commercial There be is launch. full some to additional prior work to
the with prepare commercial enhance in supply comparable more which and discuss system. manufacturing, our advancing I'll this and use regulatory use will In we x-rays, detail installation processes and coming necessary to GenesisX parallel of ablation First MAGiC foremost, catheter, are we real-world various months demonstrate the a approval moment, of efforts, regulatory and is to use of to in GenesisX. chain, towards the the compatibility
We our full new the GenesisX launch piece our MAGiC. the second adoption critical of system ablation expect ecosystem, in puzzle This into product in and foundational catheter, initial navigated significant robotically the proprietary segues XXXX. of
procedure. the in in by clinically, been XX-year-old performance. we've and design catheter on strategically past, improvement a with robotic hampered dependence clinical room ablation is the have we every commercially That significant As J&J used for in discussed our catheter
revenue design believe and of reduced many in Commercially, intuitive of every of navigation, information load. Stereotaxis or disposable better the the sales our outcomes physician procedure. patients, improve that incorporates value robbing majority the and catheter, users experience J&J from will from fluid stability, tip receives economic more robotic current MAGiC of ablation no enhancements of vast the increased revenue us we the their including
from profit us allow in While robotic a and scale MAGiC XX% up profitably we've multiply will a model our revenue gross disposable allows model, have more razor giving fashion. revenue blade of That blade. procedure. razor the organization rapidly robust business been commercial to us fairly we improved much to a every
Lastly, strategically, robot. limited around healthy J&J's develop ecosystem on our catheter a our ability to our collaborate dependence has and
some the and becoming arduous ablation clinical additional is an and The regulatory an opportunities already are possible. path. from commercialization, You've for approaching of realization that that have collaborations seen come the catheter development, MAGiC increasingly process is
MAGiC millions catheter and our commercialization. getting many cusp of proprietary have years We to dollars of the invested effort of
of application announced of this FDA for the CE to application PMA body submission notified the we a submission a Earlier and year, to Magic.
microbiology X the all distinct submissions. both X having our sections. Since by met a body sync meaningful clinical last assessment. we completed consists receipt confirmation of those We technical The have notified written sections: successfully review progress both EU clinical, in reviews on technical and and made the requirements with regulatory of of call, European
CE With generated receive have will coming to waiting study. complete of hope arise they but full and to microbiology We in of benefiting weeks. advised MAGiC section Europe, from still the launch should a clinical we the MAGiC successfully receipt that in the are experience awareness momentarily and by that the clinical initiate questions, similarly ongoing mark, been
dialogue also as European describe review U.S. The simple with post-approval clear approval, process, collaborative the the and being refined weeks. plan supports initial in for a the regulatory PMA thoughtful with there very leveraging subsequent the regulatory PMA ongoing since the the our existing U.S. guidance has submission dialogue achieving It's study MAGiC that in FDA and of guidance. to an and are submission been continuous being We've In not appreciative studies progress data discussions expectation generated the significant had is in recent and the with of but
believe ago of the a patients The who cover of importance for the appreciate depend I topic these acquisition reflective and acquire APT responsiveness and becomes to our available agreement MAGiC call ensuring at announced that closed this the will of and May are it. for the Access Point have collaborative of July. importance on week the of appreciation on final which discussions over nature We on call and and to end shared they trajectory significant want acquisition to Technologies. physicians just our a We is in
The selectivity acquisition. strong for to This rationale is were first reflective of is and for financially in synergistic was the announce our a most value the Stereotaxis' the in our the and strategic acquisition acquisition opportunistic pursued was largest conference acquisition prudent important fashion ever, immediately for field, what creation and focus. fortunate significant We before HRS.
Stereotaxis in and APT's together at the teams group, products worked conference. the were both included
on entered origins. this U.S. in skilled treatment sales a synergy. field high-quality agreement who Stereotaxis no the catheters, XX over and complex minimal focused most having differentiated natural revenue across particularly APT cognizant of the have the are We dedicated the sales of consequence and U.S. people diagnostic improving into of has had team. enabling EP the from
The we're been and were products synergies pleased before enthusiastic had They sales align strategy. perspective Efficient a team about beautifully and at full quickly the commercial from majority from APT's catheters picked exposed Stereotaxis' were and focus. of HRS. up the and Stereotaxis Stereotaxis customers the And of procedure and team while products. new to display relevant. [indiscernible] on and supportive physician products viewed the the the messaging opportunity. vast acquisition very attractive as at never These commercial both
value in commercial plans APT HRS, more purchase formal submissions Following began dozen analysis process the hospitals started team, engagement their committee of that the exposed begun the over physicians our have and a a be have field. at to establishing of catheters. able the catheters hospitals We already tried did newly training entire to and we have to
coming these building months. in approximately revenue was the XXXX. commercial monthly a we initial of the this XX% in than and or through like light average But an in are impact revenue capital is Working grow U.S. substantially more half than already year snowball believe can a seeing first products the and submission flipping higher we APT's momentum July
synergy adoption And also serve both the centers at arrhythmias reverse, contribute these the sales opener [indiscernible]. as a the on for focused The complex robotics. practices works team in of ways. revenue incremental door catheters in our pave catheters APT's path to already
was the development primary situation, and sales not nature rather in-house catheter strategic Our the synergy the nor motivation for acquiring opportunistic manufacturing having But APT value expertise. the of of
will a devices X navigated APT's as next to interventional within broader I capabilities team of of focus and range touch a procedures. want develop innovation Stereotaxis' significantly across accelerate robots amplify are There expertise efforts and to that electrophysiology we of by look of upon. wave our family are and specific areas endovascular
emerging MAGiC our First, to and expansion catheters broader family and new multi-life applications. a third, second, into complement clinical in tangible strategy; of PFH robotically steered
never field mapping past has a robotically catheter. a over EP high-density has topic, steered change the the high-density On of emergence first to Stereotaxis been the significant developed decade. mapping the
of in merit ablation from clinical not majority The there value is manual by navigates and robotically workflow a hold has hand, physician mapping strong for work but dedicated And robotically-steered our viable, steered procedures, procedural the mapping catheter. from physician a perspective the so interest catheter ideal, been a catheter. separate and
such developing complete that acquisition taking catheter design of for begun to the already with catheter accelerating place and the units testing. production now of had hundreds prior a We regulatory formal and are process
to a the MAGiC. to expect We with regulatory catheter highly year approval synergistic receive within and be
light point, the at in model embedded missed leads sound of current and to three to normal revenue revenue introduction the addition to From to transformation shine increases per sixfold numbers a Those on catheter a other product opportunity vantage structural the revenue current our any the procedure. per MAGiC the reflect five of commercial into but mapping and given ecosystem if pricing field. our participant in our perspective, a the fourfold, EP of procedure Play. increase They expected
for the as to new a energy On topic, procedures available PSA. operation frequency is ablation radio to source alternative cryo. an Post-field second or or electric ablation cardiac
already market over procedures field choice just been in The and dollars can't recognize other options but expansion. on are track energy PFA, a a can catheters PSA revenue, broader with first in existing the share our entered conversion through impact principally annual we partially and has but effects in ecosystem in procedures, protected Areas of fully importance the largely billion of of to through operating sources, field the but it catheter couple the from of the for [indiscernible]
I yet having is color activities shed I and the on of our our some our efforts. taxes
We for of distinct to of we first-in-human these in done leverages opportunities preclinical catheters. least studies at months. tandem. the the fully is the APT Catheter is have One X in being technology towards and advanced accelerating pace use and collaboration PFA owned advanced XX three unique in of recent PSA months next being and with two other MAGiC line within more in We've that X advanced collaboration an opportunities with PFA acquired are have with Two Mayo partners sight had Clinic. studies the X
commercially even Europe to likely XXXX. in is in become One available
single-shot safety Our and that some clinical the collaboration to last particularly efficacy, month. the APT design to exciting challenges and catheter differentiated commercial PSA Clinic is patient with visit PFA the addressing with durability they had Mayo starting is with opportunity emerge The of with them are catheters.
shots of technology discussed PFA expansion After last clinically goal applications starting a broader our green technologically something is we've see meaningful topic, emerge are catheters. for The the significant with of into previously. differentiated set impactful we and robotic effort, commercially shoots to multiple on
developing the interventional that late robotically-steered of interventional as expand stages the large value catheters into our We guide and of and guidewires robot fields, are radiology. such several in neurointervention, cardiology
for in be new as next are on with feedback. for and catheter guide value accelerates we the developed expertise explore these X initial ways and innovative advancing iterate track add by indications. These with manufacturing technology dramatically APT. It time the particularly to ideas ability an skilled within with will the to shared regulatory being physicians design beneficial our can catheter months is and Having prototype submission in-house
While out begin field, and accelerating we sold guide improving offering for guidewire the the to broad of value of great initial in-house to and surgery capabilities strong endovascular APT strategic are as address first catheter our expansion. the a
for profitable and platform. China, our We are which the in quarter with and business. a Synchrony efforts, for busy are healthy in us, pleased significant areas, establishing Sync making including particularly but a also substantial, progress telesurgery was in we regulatory high-growth, foundation efforts these upon a in the X other key build to Stereotaxis This
We pieces breakout geographies, our of business. falling have any over our now Europe growth. U.S., see place and in opportunity individual The driving together discuss a each I'll for opportunity geography full X Kim we financial into Kim? coming the our China, results. to the entire dwarf the ecosystem in hand to puzzle key and call can current
